合成生物学在肠道微生态疗法研发中的应用

高梦学; 王丽娜; 黄鹤

doi:10.12211/2096-8280.2021-097

您当前的位置：

首页 >

文章列表页 >

合成生物学在肠道微生态疗法研发中的应用

特约评述 | 更新时间：2025-03-20

- 合成生物学在肠道微生态疗法研发中的应用
- Advances in synthetic biology assisted intestinal microecological therapy
- 合成生物学 2022年3卷第1期页码：35-52
- 作者机构：
  
  1.天津大学化工学院，教育部合成生物学前沿科学中心，系统生物工程教育部重点实验室，天津 300072
  2.天津大学浙江绍兴研究院，浙江绍兴 312000
- 作者简介：
  
  [ "高梦学（1996—），女，博士研究生。研究方向为产维生素类营养物质活菌制剂的制备及应用。E-mail：2018207213@tju.edu.cn" ]
  [ "黄鹤（1971—），女，教授，博士生导师。研究方向为合成生物肠道菌（群）构建及应用、纳米抗体等功能生物大分子的理性设计及高效制备、耐药致病微生物代谢机理与应对策略等。E-mail：huang@tju.edu.cn" ]
- 基金信息：
  
  国家重点研发计划“合成生物学”重点专项(2019YFA09005600)
- DOI：10.12211/2096-8280.2021-097
  中图分类号： Q 81
- 收稿：2021-10-21，
  
  修回：2021-12-08，
  
  纸质出版：2022-02-28
- 稿件说明：
移动端阅览
高梦学，王丽娜，黄鹤. 合成生物学在肠道微生态疗法研发中的应用［J］. 合成生物学， 2022， 3（1）： 35-52

GAO Mengxue， WANG Lina， HUANG He. Advances in synthetic biology assisted intestinal microecological therapy［J］. Synthetic Biology Journal， 2022， 3（1）： 35-52
高梦学，王丽娜，黄鹤. 合成生物学在肠道微生态疗法研发中的应用［J］. 合成生物学， 2022， 3（1）： 35-52 DOI： 10.12211/2096-8280.2021-097.

GAO Mengxue， WANG Lina， HUANG He. Advances in synthetic biology assisted intestinal microecological therapy［J］. Synthetic Biology Journal， 2022， 3（1）： 35-52 DOI： 10.12211/2096-8280.2021-097.

摘要

肠道菌群是人体的重要“器官”。工业化世界的发展加速了对肠道菌群研究从“传统结构”向“工业结构”的转变，而纠正肠道微生态失衡已成为解决重大慢性非传染性疾病传播难题的核心策略之一。然而，目前开发的靶向调节肠道菌群结构与功能的传统微生态疗法，如益生元疗法、益生菌疗法和粪菌移植疗法，只有少数被用于临床多发难治性重大慢病的防治，且出现了可控性差、菌群遗传背景不清晰等安全问题。合成生物学技术手段的迭代发展推动了新型微生态药物的研发，成为对重大慢病进行精准识别和精准施策的关键。本文首先以消化系统疾病、代谢性疾病和精神疾病等重大慢性疾病的干预和治疗为切入点，回顾了基于合成生物学方法设计构建工程益生菌的研究进展，并对以工程益生菌为核心的微生态疗法在上述重大慢病中的应用进行了综述。同时，考虑到单一工程益生菌的负荷和抗干扰能力等问题，本文还提出了利用工程益生菌构建人工合成肠道菌群开发新一代微生态疗法的设想，分析了这一过程所面临的机遇与挑战，旨在为工程益生菌和人工合成肠道群落基础研究和临床应用的双向转化提供借鉴，从而推动新型微生态药物的研发。

Abstract

The pool of microbes inhabiting our gut is known as ‘gut microbiota’. The gut microbiota

the largest symbiotic ecosystem with the host

has been shown to play important roles in maintaining intestinal homeostasis

and its structure and function have changed significantly since the industrialization era

especially with the change of lifestyle and the improvement of health care. This microbial community regulates some important metabolic and physiological functions of the host

and drives the maturation of the immune system in early life. Dysbiosis of the gut microbiome is caused by an imbalance between the commensal and pathogenic microbiomes

and alterations of the intestinal microbiota can be directly correlated with several diseases. This remodeled ‘industrialized’ gut microbiota has a profound impact on human health

accelerating the development of major chronic diseases such as digestive

metabolic and psychiatric disorders. Therefore

correcting intestinal microecological imbalance has become one of the core strategies to address the challenges in the development of major chronic non-communicable diseases. However

only a few conventional gut microbiome therapeutics developed to target the regulation of intestinal flora structure and function

such as probiotic therapy and fecal transplantation therapy have been used for the prevention and treatment of major chronic diseases with multiple intractable clinical conditions. Moreover

safety issues such as poor controllability and unclear genetic background of the flora have emerged. The iterative development of synthetic biology and microbial culture omics technology tools have promoted the development of novel microecological drugs

which have become the key to the precise identification and effective administration of major chronic diseases. This review takes the perspective of intervention and treatment of major chronic diseases such as digestive diseases

metabolic diseases and psychiatric diseases. The research progress of synthetic biology concepts and related technologies in designing and constructing engineered probiotics is systematically discussed. The application of microbiome therapeutics focusing on engineered probiotics in 3 categories of major chronic diseases is further reviewed. Moreover

we summarize the opportunities and challenges of using engineered probiotics to build synthetic flora

aiming to providing new methods and strategies for the diagnosis and prevention of major chronic diseases

thus promoting technological innovation and development of gut microbiome therapeutics.

关键词

Keywords

references

BRODY H . The gut microbiome [J ] . Nature , 2020 , 577 ( 7792 ): S5 .

CRESCI G A , BAWDEN E . Gut microbiome: what we do and don′t know [J ] . Nutrition in Clinical Practice , 2015 , 30 ( 6 ): 734 - 746 .

VÁZQUEZ-CASTELLANOS J F , BICLOT A , VRANCKEN G , et al . Design of synthetic microbial consortia for gut microbiota modulation [J ] . Current Opinion in Pharmacology , 2019 , 49 : 52 - 59 .

DEWEERDT S . Microbiome: a complicated relationship status [J ] . Nature , 2014 , 508 ( 7496 ): S61 - S63 .

ZHAO L P . The gut microbiota and obesity: from correlation to causality [J ] . Nature Reviews Microbiology , 2013 , 11 ( 9 ): 639 - 647 .

GURUNG M , LI Z P , YOU H , et al . Role of gut microbiota in type 2 diabetes pathophysiology [J ] . EBioMedicine , 2020 , 51 : 102590 .

LIU R T , ROWAN-NASH A D , SHEEHAN A E , et al . Reductions in anti-inflammatory gut bacteria are associated with depression in a sample of young adults [J ] . Brain, Behavior, and Immunity , 2020 , 88 : 308 - 324 .

VOGT N M , KERBY R L , DILL-MCFARLAND K A , et al . Gut microbiome alterations in Alzheimer's disease [J ] . Scientific Reports , 2017 , 7 : 13537 .

ZHAO Y H , CONG L , JABER V , et al . Microbiome-derived lipopolysaccharide enriched in the perinuclear region of Alzheimer's disease brain [J ] . Frontiers in Immunology , 2017 , 8 : 1064 .

SONNENBURG J L , SONNENBURG E D . Vulnerability of the industrialized microbiota [J ] . Science , 2019 , 366 ( 6464 ): eaaw9255 .

GIBSON G R , HUTKINS R , SANDERS M E , et al . Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics [J ] . Nature Reviews Gastroenterology & Hepatology , 2017 , 14 ( 8 ): 491 - 502 .

CLAUS S P . Inulin prebiotic: is it all about bifidobacteria? [J ] . Gut , 2017 , 66 ( 11 ): 1883 - 1884 .

WILSON B , ROSSI M , KANNO T , et al . β-Galactooligosaccharide in conjunction with low FODMAP diet improves irritable bowel syndrome symptoms but reduces fecal bifidobacteria [J ] . American Journal of Gastroenterology , 2020 , 115 ( 6 ): 906 - 915 .

LILLY D M , STILLWELL R H . Probiotics: growth-promoting factors produced by microorganisms [J ] . Science , 1965 , 147 ( 3659 ): 747 - 748 .

SANDERS M E , MERENSTEIN D J , REID G , et al . Probiotics and prebiotics in intestinal health and disease: from biology to the clinic [J ] . Nature Reviews Gastroenterology & Hepatology , 2019 , 16 ( 10 ): 605 - 616 .

KRUIS W , FRIC P , POKROTNIEKS J , et al . Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine [J ] . Gut , 2004 , 53 ( 11 ): 1617 - 1623 .

MARTÍN R , MIQUEL S , BENEVIDES L , et al . Functional characterization of novel faecalibacterium prausnitzii strains isolated from healthy volunteers: a step forward in the use of F. prausnitzii as a next-generation probiotic [J ] . Frontiers in Microbiology , 2017 , 8 : 1226 .

HENN M R , O'BRIEN E J , DIAO L Y , et al . A phase 1b safety study of SER-287, a spore-based microbiome therapeutic, for active mild to moderate ulcerative colitis [J ] . Gastroenterology , 2021 , 160 ( 1 ): 115 - 127 .

CURRÒ D , IANIRO G , PECERE S , et al . Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders [J ] . British Journal of Pharmacology , 2017 , 174 ( 11 ): 1426 - 1449 .

CHEN P , XU H Y , TANG H , et al . Modulation of gut mucosal microbiota as a mechanism of probiotics-based adjunctive therapy for ulcerative colitis [J ] . Microbial Biotechnology , 2020 , 13 ( 6 ): 2032 - 2043 .

SHIN J H , NAM M H , LEE H , et al . Amelioration of obesity-related characteristics by a probiotic formulation in a high-fat diet-induced obese rat model [J ] . European Journal of Nutrition , 2018 , 57 ( 6 ): 2081 - 2090 .

KARBASCHIAN Z , MOKHTARI Z , PAZOUKI A , et al . Probiotic supplementation in morbid obese patients undergoing one anastomosis gastric bypass-mini gastric bypass (OAGB-MGB) surgery: a randomized, double-blind, placebo-controlled, clinical trial [J ] . Obesity Surgery , 2018 , 28 ( 9 ): 2874 - 2885 .

SABICO S , AL-MASHHARAWI A , AL-DAGHRI N M , et al . Effects of a multi-strain probiotic supplement for 12 weeks in circulating endotoxin levels and cardiometabolic profiles of medication naïve T2DM patients: a randomized clinical trial [J ] . Journal of Translational Medicine , 2017 , 15 ( 1 ): 249 .

PERRAUDEAU F , MCMURDIE P , BULLARD J , et al . Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation [J ] . BMJ Open Diabetes Research & Care , 2020 , 8 ( 1 ): e001319 .

MALDONADO-GÓMEZ M X , MARTÍNEZ I , BOTTACINI F , et al . Stable engraftment of bifidobacterium longum AH1206 in the human gut depends on individualized features of the resident microbiome [J ] . Cell Host & Microbe , 2016 , 20 ( 4 ): 515 - 526 .

MARX W , SCHOLEY A , FIRTH J , et al . Prebiotics, probiotics, fermented foods and cognitive outcomes: a meta-analysis of randomized controlled trials [J ] . Neuroscience & Biobehavioral Reviews , 2020 , 118 : 472 - 484 .

WILSON B , ROSSI M , DIMIDI E , et al . Prebiotics in irritable bowel syndrome and other functional bowel disorders in adults: a systematic review and meta-analysis of randomized controlled trials [J ] . American Journal of Clinical Nutrition , 2019 , 109 ( 4 ): 1098 - 1111 .

COSTELOE K , HARDY P , JUSZCZAK E , et al . Bifidobacterium breve BBG-001 in very preterm infants: a randomised controlled phase 3 trial [J ] . Lancet , 2016 , 387 ( 10019 ): 649 - 660 .

FREEDMAN S B , FINKELSTEIN Y , PANG X L , et al . Pathogen-specific effects of probiotics in children with acute gastroenteritis seeking emergency care: a randomized trial [J ] . Clinical Infectious Diseases , 2021 , https://doi.org/10.1093/cid/ciab876 https://doi.org/10.1093/cid/ciab876 .

JOHNSTONE J , MEADE M , LAUZIER F , et al . Effect of probiotics on incident ventilator-associated pneumonia in critically ill patients: a randomized clinical trial [J ] . JAMA , 2021 , 326 ( 11 ): 1024 - 1033 .

ZHANG F M , CUI B T , HE X X , et al . Microbiota transplantation: concept, methodology and strategy for its modernization [J ] . Protein & Cell , 2018 , 9 ( 5 ): 462 - 473 .

MULLISH B H , QURAISHI M N , SEGAL J P , et al . The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines [J ] . Gut , 2018 , 67 ( 11 ): 1920 - 1941 .

DEFILIPP Z , BLOOM P P , TORRES SOTO M , et al . Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant [J ] . New England Journal of Medicine , 2019 , 381 ( 21 ): 2043 - 2050 .

丁明珠 , 李炳志 , 王颖 , 等 . 合成生物学重要研究方向进展 [J ] . 合成生物学 , 2020 , 1 ( 1 ): 7 - 28 .

DING M Z , LI B Z , WANG Y , et al . Significant research progress in synthetic biology [J ] . Synthetic Biology Journal , 2020 , 1 ( 1 ): 7 - 28 .

RIGLAR D T , SILVER P A . Engineering bacteria for diagnostic and therapeutic applications [J ] . Nature Reviews Microbiology , 2018 , 16 ( 4 ): 214 - 225 .

MCCARTY N S , LEDESMA-AMARO R . Synthetic biology tools to engineer microbial communities for biotechnology [J ] . Trends in Biotechnology , 2019 , 37 ( 2 ): 181 - 197 .

PEDROLLI D B , RIBEIRO N V , SQUIZATO P N , et al . Engineering microbial living therapeutics: the synthetic biology toolbox [J ] . Trends in Biotechnology , 2019 , 37 ( 1 ): 100 - 115 .

GOH Y J , BARRANGOU R . Harnessing CRISPR-Cas systems for precision engineering of designer probiotic lactobacilli [J ] . Current Opinion in Biotechnology , 2019 , 56 : 163 - 171 .

PETERS J M , KOO B M , PATINO R , et al . Enabling genetic analysis of diverse bacteria with Mobile-CRISPRi [J ] . Nature Microbiology , 2019 , 4 ( 2 ): 244 - 250 .

GAO C , XU P , YE C , et al . Genetic circuit-assisted smart microbial engineering [J ] . Trends in Microbiology , 2019 , 27 ( 12 ): 1011 - 1024 .

WINDSOR J W , KAPLAN G G . Evolving epidemiology of IBD [J ] . Current Gastroenterology Reports , 2019 , 21 ( 8 ): 40 .

KEUM N , GIOVANNUCCI E . Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies [J ] . Nature Reviews Gastroenterology & Hepatology , 2019 , 16 ( 12 ): 713 - 732 .

SOMMER F , RÜHLEMANN M C , BANG C , et al . Microbiomarkers in inflammatory bowel diseases: caveats come with caviar [J ] . Gut , 2017 , 66 ( 10 ): 1734 - 1738 .

TILG H , ADOLPH T E , GERNER R R , et al . The intestinal microbiota in colorectal cancer [J ] . Cancer Cell , 2018 , 33 ( 6 ): 954 - 964 .

HODSON R . Inflammatory bowel disease [J ] . Nature , 2016 , 540 ( 7634 ): S97 .

DORDEVIĆ D , JANČÍKOVÁ S , VÍTĚZOVÁ M , et al . Hydrogen sulfide toxicity in the gut environment: meta-analysis of sulfate-reducing and lactic acid bacteria in inflammatory processes [J ] . Journal of Advanced Research , 2021 , 27 : 55 - 69 .

DAEFFLER K N M , GALLEY J D , SHETH R U , et al . Engineering bacterial thiosulfate and tetrathionate sensors for detecting gut inflammation [J ] . Molecular Systems Biology , 2017 , 13 ( 4 ): 923 .

WOO S G , MOON S J , KIM S K , et al . A designed whole-cell biosensor for live diagnosis of gut inflammation through nitrate sensing [J ] . Biosensors and Bioelectronics , 2020 , 168 : 112523 .

MIMEE M , NADEAU P , HAYWARD A , et al . An ingestible bacterial-electronic system to monitor gastrointestinal health [J ] . Science , 2018 , 360 ( 6391 ): 915 - 918 .

STEIDLER L , HANS W , SCHOTTE L , et al . Treatment of murine colitis by Lactococcus lactis secreting interleukin-10 [J ] . Science , 2000 , 289 ( 5483 ): 1352 - 1355 .

VANDENBROUCKE K , DE HAARD H , BEIRNAERT E , et al . Orally administered L. lactis secreting an anti-TNF nanobody demonstrate efficacy in chronic colitis [J ] . Mucosal Immunology , 2010 , 3 ( 1 ): 49 - 56 .

SCOTT B M , GUTIÉRREZ-VÁZQUEZ C , SANMARCO L M , et al . Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease [J ] . Nature Medicine , 2021 , 27 ( 7 ): 1212 - 1222 .

MAYS Z J , NAIR N U . Synthetic biology in probiotic lactic acid bacteria: at the frontier of living therapeutics [J ] . Current Opinion in Biotechnology , 2018 , 53 : 224 - 231 .

DOU J , BENNETT M R . Synthetic biology and the gut microbiome [J ] . Biotechnology Journal , 2018 , 13 ( 5 ): e1700159 .

YAN X , LIU X Y , ZHANG D , et al . Construction of a sustainable 3-hydroxybutyrate-producing probiotic Escherichia coli for treatment of colitis [J ] . Cellular & Molecular Immunology , 2021 , 18 ( 10 ): 2344 - 2357 .

CUI M H , PANG G J , ZHANG T , et al . Optotheranostic nanosystem with phone visual diagnosis and optogenetic microbial therapy for ulcerative colitis at-home care [J ] . ACS Nano , 2021 , 15 ( 4 ): 7040 - 7052 .

PRAVESCHOTINUNT P , DURAJ-THATTE A M , GELFAT I , et al . Engineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut [J ] . Nature Communications , 2019 , 10 : 5580 .

YAN Z F , YIN M , CHEN J N , et al . Assembly and substrate recognition of curli biogenesis system [J ] . Nature Communications , 2020 , 11 : 241 .

YU M , KIM J , AHN J H , et al . Nononcogenic restoration of the intestinal barrier by E. coli -delivered human EGF [J ] . JCI Insight , 2019 , 4 ( 16 ): e125166 .

NADEEM M S , KUMAR V , AL-ABBASI F A , et al . Risk of colorectal cancer in inflammatory bowel diseases [J ] . Seminars in Cancer Biology , 2020 , 64 : 51 - 60 .

DAI Z W , COKER O O , NAKATSU G , et al . Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers [J ] . Microbiome , 2018 , 6 ( 1 ): 70 .

HO C L , TAN H Q , CHUA K J , et al . Engineered commensal microbes for diet-mediated colorectal-cancer chemoprevention [J ] . Nature Biomedical Engineering , 2018 , 2 ( 1 ): 27 - 37 .

AN B C , RYU Y , YOON Y S , et al . Colorectal cancer therapy using a pediococcus pentosaceus SL4 drug delivery system secreting lactic acid bacteria-derived protein p8 [J ] . Molecules and Cells , 2019 , 42 ( 11 ): 755 - 762 .

CHEN J H , LI X H , LIU Y M , et al . Engineering a probiotic strain of Escherichia coli to induce the regression of colorectal cancer through production of 5-aminolevulinic acid [J ] . Microbial Biotechnology , 2021 , 14 ( 5 ): 2130 - 2139 .

CANI P D . Microbiota and metabolites in metabolic diseases [J ] . Nature Reviews Endocrinology , 2019 , 15 ( 2 ): 69 - 70 .

HE Y , WU W , WU S , et al . Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis [J ] . Microbiome , 2018 , 6 ( 1 ): 172 .

BROUSSARD J L , DEVKOTA S . The changing microbial landscape of Western society: diet, dwellings and discordance [J ] . Molecular Metabolism , 2016 , 5 ( 9 ): 737 - 742 .

CABALLERO B . Humans against obesity: who will win? [J ] . Advances in Nutrition , 2019 , 10 ( suppl_1 ): S4 - S9 .

FEI N , BRUNEAU A , ZHANG X J , et al . Endotoxin producers overgrowing in human gut microbiota as the causative agents for nonalcoholic fatty liver disease [J ] . mBio , 2020 , 11 ( 1 ): e03263 - e03219 .

ZHAO L P , ZHAO N S . Demonstration of causality: back to cultures [J ] . Nature Reviews Gastroenterology & Hepatology , 2021 , 18 ( 2 ): 97 - 98 .

LE CHATELIER E , NIELSEN T , QIN J J , et al . Richness of human gut microbiome correlates with metabolic markers [J ] . Nature , 2013 , 500 ( 7464 ): 541 - 546 .

WADDEN T A , VOLGER S , TSAI A G , et al . Managing obesity in primary care practice: an overview with perspective from the POWER-UP study [J ] . International Journal of Obesity , 2013 , 37 ( 1 ): S3 - S11 .

THEREAUX J , LESUFFLEUR T , CZERNICHOW S , et al . Long-term adverse events after sleeve gastrectomy or gastric bypass: A 7-year nationwide, observational, population-based, cohort study [J ] . The Lancet Diabetes & Endocrinology , 2019 , 7 ( 10 ): 786 - 795 .

HIRA T , PINYO J , HARA H . What is GLP-1 really doing in obesity? [J ] . Trends in Endocrinology & Metabolism , 2020 , 31 ( 2 ): 71 - 80 .

WANG L F , CHEN T T , WANG H , et al . Engineered bacteria of MG1363-pMG36e-GLP-1 attenuated obesity-induced by high fat diet in mice [J ] . Frontiers in Cellular and Infection Microbiology , 2021 , 11 : 595575 .

MA J , LI C Y , WANG J R , et al . Genetically engineered Escherichia coli nissle 1917 secreting GLP-1 analog exhibits potential antiobesity effect in high-fat diet-induced obesity mice [J ] . Obesity , 2020 , 28 ( 2 ): 315 - 322 .

LONG R T , ZENG W S , CHEN L Y , et al . Bifidobacterium as an oral delivery carrier of oxyntomodulin for obesity therapy: inhibitory effects on food intake and body weight in overweight mice [J ] . International Journal of Obesity , 2010 , 34 ( 4 ): 712 - 719 .

NAMAI F , SHIGEMORI S , SUDO K , et al . Recombinant mouse osteocalcin secreted by Lactococcus lactis promotes glucagon-like peptide-1 induction in STC-1 cells [J ] . Current Microbiology , 2018 , 75 ( 1 ): 92 - 98 .

CAO W Y , DONG M , HU Z Y , et al . Recombinant Lactococcus lactis NZ3900 expressing bioactive human FGF21 reduced body weight of Db/Db mice through the activity of brown adipose tissue [J ] . Beneficial Microbes , 2020 , 11 ( 1 ): 67 - 78 .

CHEN Z Y , GUO L L , ZHANG Y Q , et al . Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity [J ] . Journal of Clinical Investigation , 2014 , 124 ( 8 ): 3391 - 3406 .

DOSOKY N S , GUO L L , CHEN Z Y , et al . Dietary fatty acids control the species of N -acyl-phosphatidylethanolamines synthesized by therapeutically modified bacteria in the intestinal tract [J ] . ACS Infectious Diseases , 2018 , 4 ( 1 ): 3 - 13 .

BAI L , GAO M X , CHENG X M , et al . Engineered butyrate-producing bacteria prevents high fat diet-induced obesity in mice [J ] . Microbial Cell Factories , 2020 , 19 ( 1 ): 94 .

GUTHRIE R A , GUTHRIE D W . Pathophysiology of diabetes mellitus [J ] . Critical Care Nursing Quarterly , 2004 , 27 ( 2 ): 113 - 125 .

PAUN A , DANSKA J S . Modulation of type 1 and type 2 diabetes risk by the intestinal microbiome [J ] . Pediatric Diabetes , 2016 , 17 ( 7 ): 469 - 477 .

NEEDELL J C , ZIPRIS D . The role of the intestinal microbiome in type 1 diabetes pathogenesis [J ] . Current Diabetes Reports , 2016 , 16 ( 10 ): 89 .

TAN S Y , WONG J L M , SIM Y J , et al . Type 1 and 2 diabetes mellitus: a review on current treatment approach and gene therapy as potential intervention [J ] . Diabetes & Metabolic Syndrome: Clinical Research & Reviews , 2019 , 13 ( 1 ): 364 - 372 .

ROBERT S , GYSEMANS C , TAKIISHI T , et al . Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice [J ] . Diabetes , 2014 , 63 ( 8 ): 2876 - 2887 .

TAKIISHI T , KORF H , VAN BELLE T L , et al . Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice [J ] . Journal of Clinical Investigation , 2012 , 122 ( 5 ): 1717 - 1725 .

LANG J C , WANG X K , LIU K F , et al . Oral delivery of staphylococcal nuclease by Lactococcus lactis prevents type 1 diabetes mellitus in NOD mice [J ] . Applied Microbiology and Biotechnology , 2017 , 101 ( 20 ): 7653 - 7662 .

MA Y J , LIU J J , HOU J , et al . Oral administration of recombinant Lactococcus lactis expre ssing HSP65 and tandemly repeated P277 reduces the incidence of type I diabetes in non-obese diabetic mice [J ] . PLoS One , 2014 , 9 ( 8 ): e105701 .

AGARWAL P , KHATRI P , BILLACK B , et al . Oral delivery of glucagon like peptide-1 by a recombinant Lactococcus lactis [J ] . Pharmaceutical Research , 2014 , 31 ( 12 ): 3404 - 3414 .

DUAN F F , LIU J H , MARCH J C . Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes [J ] . Diabetes , 2015 , 64 ( 5 ): 1794 - 1803 .

ZENG Z , YU R , ZUO F L , et al . Recombinant Lactococcus lactis expressing bioactive exendin-4 to promote insulin secretion and beta-cell proliferation in vitro [J ] . Applied Microbiology and Biotechnology , 2017 , 101 ( 19 ): 7177 - 7186 .

RHIMI M , BERMUDEZ-HUMARAN L G , HUANG Y , et al . The secreted L-arabinose isomerase displays anti-hyperglycemic effects in mice [J ] . Microbial Cell Factories , 2015 , 14 : 204 .

GMITROWICZ A , KUCHARSKA A . Developmental disorders in the fourth edition of the American classification: diagnostic and statistical manual of mental disorders (DSM IV — optional book) [J ] . Psychiatria Polska , 1994 , 28 ( 5 ): 509 - 521 .

SMITH K . Mental health: a world of depression [J ] . Nature , 2014 , 515 ( 7526 ): 181 .

CHOPRA K , KUMAR B , KUHAD A . Pathobiological targets of depression [J ] . Expert Opinion on Therapeutic Targets , 2011 , 15 ( 4 ): 379 - 400 .

SIMPSON C A , DIAZ-ARTECHE C , ELIBY D , et al . The gut microbiota in anxiety and depression-a systematic review [J ] . Clinical Psychology Review , 2021 , 83 : 101943 .

ZHENG P , ZENG B , ZHOU C , et al . Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism [J ] . Molecular Psychiatry , 2016 , 21 ( 6 ): 786 - 796 .

STRANDWITZ P , KIM K H , TEREKHOVA D , et al . GABA-modulating bacteria of the human gut microbiota [J ] . Nature Microbiology , 2019 , 4 ( 3 ): 396 - 403 .

MEDINA-RODRIGUEZ E M , MADORMA D , O'CONNOR G , et al . Identification of a signaling mechanism by which the microbiome regulates Th17 cell-mediated depressive-like behaviors in mice [J ] . The American Journal of Psychiatry , 2020 , 177 ( 10 ): 974 - 990 .

DINAN T G , STANTON C , CRYAN J F . Psychobiotics: a novel class of psychotropic [J ] . Biological Psychiatry , 2013 , 74 ( 10 ): 720 - 726 .

BAMBURY A , SANDHU K , CRYAN J F , et al . Finding the needle in the haystack: systematic identification of psychobiotics [J ] . British Journal of Pharmacology , 2018 , 175 ( 24 ): 4430 - 4438 .

XU D , FANG M J , WANG H J , et al . Enhanced production of 5-hydroxytryptophan through the regulation of L-tryptophan biosynthetic pathway [J ] . Applied Microbiology and Biotechnology , 2020 , 104 ( 6 ): 2481 - 2488 .

LÜ C J , ZHAO W R , HU S , et al . Physiology-oriented engineering strategy to improve gamma-aminobutyrate production in Lactobacillus brevis [J ] . Journal of Agricultural and Food Chemistry , 2017 , 65 ( 4 ): 858 - 866 .

VAN DUNG PHAM , SOMASUNDARAM S , LEE S H , et al . Efficient production of gamma-aminobutyric acid using Escherichia coli by co-localization of glutamate synthase, glutamate decarboxylase, and GABA transporter [J ] . Journal of Industrial Microbiology and Biotechnology , 2016 , 43 ( 1 ): 79 - 86 .

DEN H , DONG X H , CHEN M L , et al . Efficacy of probiotics on cognition, and biomarkers of inflammation and oxidative stress in adults with Alzheimer's disease or mild cognitive impairment - a meta-analysis of randomized controlled trials [J ] . Aging , 2020 , 12 ( 4 ): 4010 - 4039 .

ZHAO Y H , JABER V , LUKIW W J . Secretory products of the human GI tract microbiome and their potential impact on Alzheimer's disease (AD): detection of lipopolysaccharide (LPS) in AD hippocampus [J ] . Frontiers in Cellular and Infection Microbiology , 2017 , 7 : 318 .

FANG X , ZHOU X T , MIAO Y Q , et al . Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer's disease and Parkinson's disease [J ] . AMB Express , 2020 , 10 ( 1 ): 80 .

CHEN T T , TIAN P Y , HUANG Z X , et al . Engineered commensal bacteria prevent systemic inflammation-induced memory impairment and amyloidogenesis via producing GLP-1 [J ] . Applied Microbiology and Biotechnology , 2018 , 102 ( 17 ): 7565 - 7575 .

YAMAOKA M , OSAWA S , MORINAGA T , et al . A cell factory of Bacillus subtilis engineered for the simple bioconversion of myo-inositol to scyllo-inositol, a potential therapeutic agent for Alzheimer's disease [J ] . Microbial Cell Factories , 2011 , 10 : 69 .

CECARINI V , BONFILI L , GOGOI O , et al . Neuroprotective effects of p62(SQSTM1)-engineered lactic acid bacteria in Alzheimer's disease: a pre-clinical study [J ] . Aging , 2020 , 12 ( 16 ): 15995 - 16020 .

KIM S , KERNS S J , ZIESACK M , et al . Quorum sensing can be repurposed to promote information transfer between bacteria in the mammalian gut [J ] . ACS Synthetic Biology , 2018 , 7 ( 9 ): 2270 - 2281 .

CAMACHO D M , COLLINS K M , POWERS R K , et al . Next-generation machine learning for biological networks [J ] . Cell , 2018 , 173 ( 7 ): 1581 - 1592 .

JIAO N , BAKER S S , NUGENT C A , et al . Gut microbiome may contribute to insulin resistance and systemic inflammation in obese rodents: a meta-analysis [J ] . Physiological Genomics , 2018 , 50 ( 4 ): 244 - 254 .

GUO X F , LI S H , ZHANG J C , et al . Genome sequencing of 39 Akkermansia muciniphila isolates reveals its population structure, genomic and functional diverisity, and global distribution in mammalian gut microbiotas [J ] . BMC Genomics , 2017 , 18 ( 1 ): 800 .

KAPSE N G , ENGINEER A S , GOWDAMAN V , et al . Functional annotation of the genome unravels probiotic potential of Bacillus coagulans HS243 [J ] . Genomics , 2019 , 111 ( 4 ): 921 - 929 .

MEDLOCK G L , CAREY M A , MCDUFFIE D G , et al . Inferring metabolic mechanisms of interaction within a defined gut microbiota [J ] . Cell Systems , 2018 , 7 ( 3 ): 245 - 257 .

URIBE R V , VAN DER HELM E , MISIAKOU M A , et al . Discovery and characterization of Cas9 inhibitors disseminated across seven bacterial phyla [J ] . Cell Host & Microbe , 2019 , 25 ( 2 ): 233 - 241 .

LAWSON C E , HARCOMBE W R , HATZENPICHLER R , et al . Common principles and best practices for engineering microbiomes [J ] . Nature Reviews Microbiology , 2019 , 17 ( 12 ): 725 - 741 .

SHAH P , FRITZ J V , GLAAB E , et al . A microfluidics-based in vitro model of the gastrointestinal human-microbe interface [J ] . Nature Communications , 2016 , 7 : 11535 .

TSAKMAKI A , FONSECA PEDRO P , BEWICK G A . 3D intestinal organoids in metabolic research: virtual reality in a dish [J ] . Current Opinion in Pharmacology , 2017 , 37 : 51 - 58 .

INGBER D E . Reverse engineering human pathophysiology with organs-on-chips [J ] . Cell , 2016 , 164 ( 6 ): 1105 - 1109 .

UZBAY T . Germ-free animal experiments in the gut microbiota studies [J ] . Current Opinion in Pharmacology , 2019 , 49 : 6 - 10 .

KOVATCHEVA-DATCHARY P , SHOAIE S , LEE S , et al . Simplified intestinal microbiota to study microbe-diet-host interactions in a mouse model [J ] . Cell Reports , 2019 , 26 ( 13 ): 3772 - 3783 .

REARDON S . Genetically modified bacteria enlisted in fight against disease [J ] . Nature , 2018 , 558 ( 7711 ): 497 - 498 .

KURTZ C B , MILLET Y A , PUURUNEN M K , et al . An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans [J ] . Science Translational Medicine , 2019 , 11 ( 475 ): eaau7975 .

ISABELLA V M , HA B N , CASTILLO M J , et al . Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria [J ] . Nature Biotechnology , 2018 , 36 ( 9 ): 857 - 864 .

BERMÚDEZ-HUMARÁN L G , LANGELLA P . Live bacterial biotherapeutics in the clinic [J ] . Nature Biotechnology , 2018 , 36 ( 9 ): 816 - 818 .

WEGMANN U , CARVALHO A L , STOCKS M , et al . Use of genetically modified bacteria for drug delivery in humans: Revisiting the safety aspect [J ] . Scientific Reports , 2017 , 7 : 2294 .

ALAYANDE K A , AIYEGORO O A , NENGWEKHULU T M , et al . Integrated genome-based probiotic relevance and safety evaluation of Lactobacillus reuteri PNW 1 [J ] . PLoS One , 2020 , 15 ( 7 ): e0235873 .

DO CARMO F L R , RABAH H , DE OLIVEIRA CARVALHO R D , et al . Extractable bacterial surface proteins in probiotic-host interaction [J ] . Frontiers in Microbiology , 2018 , 9 : 645 .

SONG W Z , WEMHEUER B , ZHANG S , et al . MetaCHIP: community-level horizontal gene transfer identification through the combination of best-match and phylogenetic approaches [J ] . Microbiome , 2019 , 7 ( 1 ): 36 .

TANOUE T , MORITA S , PLICHTA D R , et al . A defined commensal consortium elicits CD8 T cells and anti-cancer immunity [J ] . Nature , 2019 , 565 ( 7741 ): 600 - 605 .

WU S B , LIU J H , LIU C J , et al . Quorum sensing for population-level control of bacteria and potential therapeutic applications [J ] . Cellular and Molecular Life Sciences , 2020 , 77 ( 7 ): 1319 - 1343 .

ZIESACK M , GIBSON T , OLIVER J K W , et al . Engineered inter species amino acid cross-feeding increases population evenness in a synthetic bacterial consortium [J ] . mSystems , 2019 , 4 ( 4 ): e00352 - e00319 .

DURAJ-THATTE A M , COURCHESNE N M D , PRAVESCHOTINUNT P , et al . Genetically programmable self-regenerating bacterial hydrogels [J ] . Advanced Materials , 2019 , 31 ( 40 ): 1970289 .

CHIEN T , HARIMOTO T , KEPECS B , et al . Enhancing the tropism of bacteria via genetically programmed biosensors [J ] . Nature Biomedical Engineering , 2021 : 1 - 11 .

MAYS Z J S , CHAPPELL T C , NAIR N U . Quantifying and engineering mucus adhesion of probiotics [J ] . ACS Synthetic Biology , 2020 , 9 ( 2 ): 356 - 367 .

CHAPPELL T C , NAIR N U . Engineered lactobacilli display anti-biofilm and growth suppressing activities against Pseudomonas aeruginosa [J ] . NPJ Biofilms and Microbiomes , 2020 , 6 : 48 .

PUURUNEN M K , VOCKLEY J , SEARLE S L , et al . Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study [J ] . Nature Metabolism , 2021 , 3 ( 8 ): 1125 - 1132 .

ADOLFSEN K J , CALLIHAN I , MONAHAN C E , et al . Improvement of a synthetic live bacterial therapeutic for phenylketonuria with biosensor-enabled enzyme engineering [J ] . Nature Communications , 2021 , 12 : 6215 .

WANG L L W , JANES M E , KUMBHOJKAR N , et al . Cell therapies in the clinic [J ] . Bioengineering & Translational Medicine , 2021 , 6 ( 2 ): e10214 .

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

活体生物药在代谢类疾病中的研究

构建根际合成微生物菌群促进作物养分高效吸收利用

益生菌辅助防治恶性肿瘤的研究进展

基于表面涂层益生菌的肿瘤抗原口服递送系统